COMMUNIQUÉS West-GlobeNewswire

FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
12/02/2026
White Oak, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration has approved drug labeling changes to six menopausal hormone therapy products, also known as hormone replacement therapy (HRT), to [...]
Canadian Red Cross launches appeal to support people impacted by the tragedy in Tumbler Ridge, B.C.
12/02/2026
OTTAWA, Ontario, Feb. 12, 2026 (GLOBE NEWSWIRE) -- The Canadian Red Cross is working to support those impacted by the tragedy in Tumbler Ridge, B.C., and has launched the Tumbler Ridge Tragedy Appeal. Money raised will [...]
GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales
12/02/2026
Ipsen reported US$88M of Iqirvo® net sales in PBC for 4Q25, bringing 2025 sales to US$208M, triggering the first commercial milestone payment to GENFIT ahead of schedule 1 Ipsen confirmed its commitment to launch a [...]
Beacon Behavioral Partners Expands into South Carolina with Carolina Psychiatry
12/02/2026
New partner brings advanced depression treatments to Anderson, Greenville, Seneca, and Spartanburg BATON ROUGE, La., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Beacon Behavioral Partners (BBP), a physician-driven organization [...]
Northwestern Medicine and Founders Factory to scale European AI ventures into America’s leading health system
12/02/2026
AI is driving healthcare’s next wave: AI and deeptech advancements are transforming healthcare infrastructure, delivering novel approaches to safer, more efficient and more personalised patient care Advancing innovation [...]
Pennant Announces Fourth Quarter and Year-End 2025 Earnings Release and Call
12/02/2026
EAGLE, Idaho, Feb. 12, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announced today that it [...]
CorMedix to Participate in Upcoming Investor Conferences
12/02/2026
BERKELEY HEIGHTS, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases [...]
Healthtech Newcomer T·TIME Launches Affordable TRT Alternative
12/02/2026
New men’s telehealth clinic offers injection-free testosterone optimization with enclomiphene, 24/7 medical oversight and all-inclusive monthly pricing AUSTIN, Texas, Feb. 12, 2026 (GLOBE NEWSWIRE) -- T·TIME , a men’s [...]
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
12/02/2026
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, February 19th at 4:00 PM ET Event to focus on lead program, Ampligen, for treatment of pancreatic cancer OCALA, Fla., Feb. 12, [...]
Athelas Home Expands AI Diagnostics to the Point of Care with FDA Clearance
12/02/2026
MOUNTAIN VIEW, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Athelas, a Commure company, today announced that the FDA cleared the CLIA-waived Athelas Home diagnostic device for use in point-of-care settings. The AI-powered [...]
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
12/02/2026
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
PsiThera to Participate in Piper Sandler Virtual Novel Targets in Immunology Symposium
12/02/2026
WATERTOWN, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PsiThera, Inc. today announced that Chief Executive Officer Eric Shaff, Founder and Chief Innovation Officer Woody Sherman, Ph.D., and Chief Scientific Officer Camil [...]
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
12/02/2026
New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea’s WEE1 and ATR programs. Core patent families are expected to provide exclusivity into 2045. Lead WEE1 inhibitor candidate APR-1051 [...]
Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year
12/02/2026
First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins [...]
NMDP Appoints Ginna Laport, MD, to New Senior Physician Leadership Role
12/02/2026
Dr. Laport brings 30 years of multi-disciplinary experience across academia, national leadership positions, and industry to advance clinical practice of NMDP cell therapy research MINNEAPOLIS, Feb. 12, 2026 (GLOBE [...]
Vericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026
12/02/2026
CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report [...]
Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia
12/02/2026
- Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value commercial [...]
Microbot Medical®’s LIBERTY® Endovascular Robotic System Highlighted at a Leading Vascular Disease Management Conference
12/02/2026
International Symposium on Endovascular Therapy (ISET) Convened Key Opinion Leaders to Discuss Advancements and Future Role of Endovascular Robotics LIBERTY ® Continues to Gain Commercial Traction and Exposure as Part [...]
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
12/02/2026
- The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the 12-month [...]

Pages